See the DrugPatentWatch profile for ruxolitinib

Ruxolitinib is a medication used to treat myelofibrosis and polycythemia vera, two types of blood cancer. Azacitidine is another medication used to treat myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. There has been research into the combination of ruxolitinib and azacitidine as a potential treatment for myelodysplastic syndromes and acute myeloid leukemia.

A study published in the journal "Blood" in 2019 found that the combination of ruxolitinib and azacitidine was well-tolerated and showed promising efficacy in patients with myelodysplastic syndromes and acute myeloid leukemia. The study concluded that the combination of ruxolitinib and azacitidine "deserves further investigation" as a potential treatment for these conditions.

It is important to note that while the study suggests that the combination of ruxolitinib and azacitidine may be effective, more research is needed to confirm these findings and to determine the optimal dosing and sequencing of these medications.

In addition, it is worth noting that ruxolitinib is currently patent-protected, with the patent set to expire in 2027 [1]. Azacitidine, on the other hand, is no longer patent-protected, meaning that generic versions of the drug are available [2].

In summary, the combination of ruxolitinib and azacitidine has shown promising efficacy in the treatment of myelodysplastic syndromes and acute myeloid leukemia, but more research is needed to confirm these findings. Ruxolitinib is currently patent-protected, while azacitidine is not.

Sources:

1. [DrugPatentWatch.com - Ruxolitinib](https://www.drugpatentwatch.com/patent/IN255350)
2. [DrugPatentWatch.com - Azacitidine](https://www.drugpatentwatch.com/patent/US5674949)